Member Info for RayPointer

So you need either

a) A large number of patients to prove statistical significance if the survival improvement is small
or
b) A median survival time that is well beyond the norm

Even with the survival example I gave the vaccine still needs to go through a Phase 3 trial before approval is granted

Now if you had a trial comprising 16 stage 3/4 (mostly stage 4) patients and only 2 had died after 5 years, that would be statistically significant

Obviously a put up job LOL

The intriguing possibility is that BionTech may want to get their own TCR trial going using Modi1 ASAP.

In time to get data before their planned IPO.

Obviously, before they can do that they need to do a deal with Scancell.

I'm not saying that Moditope will determine when the IPO takes place. It is just that, the more quality clinical data before a planned IPO, the better it will be for BionTech

"The breadth of BioNTech’s early-phase pipeline and size of the series A mean it has a chance to put together clinical data packages before wooing public investors"

Now that's very interesting and surely very relevant to Moditope and Scancell.

It doesn't seem to make much difference to the running of the company.
The company still is subject to the company and tax laws for the country in which it is based

The main difference is

"The European Company Regulation is complemented by an Employee Involvement Directive that sets rules for participation by employees on the company's board of directors."

And also

"Such a company may more easily transfer to or merge with companies in other member states."

https://en.wikipedia.org/wiki/Societas_Europaea

Crumbs, isn't that DURRANT and associates LOL

I, for one, would be very surprised if we did not win.

That is no disrespect to the other entrants, I just think Lindy's project trumps the others on the ambitious initial scope. A scope that could well grow and grow over the coming years. As well as a new vaccine aimed at cancers with poor prognoses it also encompasses TCR treatment and diagnostics aimed at giving the correct combination of treatments/vaccines. Lets not forget the entry title "Eradicating tumours with personalised cancer vaccines".
"Eradicating" is the key word!

And just compare the credentials of PBP team members compared to other teams.

Well they are already a well respected company doing deals with big pharma.
I would have thought Frankfurt and the Nasdaq for starters.
They certainly would attract a lot of investors in the US.

Maybe Biontech now pretty well know what they are going to base their 1st clinical TCR trial on.
Any guesses what that might be?

Crumbs' post 10:24 last Sunday

Start of trial was originally planned for H1 2019 but at the AGM I recall they talked about 2019 (they left off the H1). We don't really know how big a delay was caused by the problem in manufacture but we know there was a delay.

The last placing was meant to last us until some time in 2020 so we should not see a placing this year, or if we do, it will be towards the end of the year. The planned spend for 2019 should actually be reduced due to the delay in trials.

But remember we still have the Biontech iron in the fire so we may not have any further dilutions. Have a look at crumb's advent calendar for 2019 posted recently. Be nice if crumbs is right. LOL

I think the problem is that the data feed from the MMs does not include whether a transaction is a buy or sell but does include the bid, the ask and the execution price.
So, it is then left to sites like LSE to have some logic to determine whether the transaction was a buy or a sell.
This logic will vary from site to site, hence on some sites transactions at 2.49 may be listed as a buy.

I don't think it was ever mentioned how long the delay was.
Originally the CTA was planned towards the end of 2018 with the start of trial 2019 H1.

It was talked about in the AGM by Sally as a delay in manufacture of Modi1.
That particular problem was sorted out by Lindy.

http://events.marketsandmarkets.com/3rd-Annual-MarketsandMarkets-Next-Gen%20Immuno-Oncology-Congress

In fact that team seems a little strange. It has has a "Chief data officer" who works for Sainsburys.

https://www.cancerresearchuk.org/funding-for-researchers/how-we-deliver-research/grand-challenge-award/shortlistedteamfaithfull

This team in fact

I seem to remember one of the "AI" teams has somebody from Microsoft.

Good point crumbs. If all the teams comprised academics and lay people the result could be announced anytime.
But could it also be that churches throughout the land want to ring in Scancell's victory LOL